KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual Commitments And ObligationsCost Of SalesDevelopment ExpensesEffective Tax Rate %Employees By RegionGross Margin %Gross ProfitIncome Before Income Taxes By RegionInventory BreakdownLong Lived Assets By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX BreakdownProduct Revenue By RegionProduct Revenue By Region %Product Revenue By Region AnnualProduct Revenue By Region Annual %Property And Equipment BreakdownResearch Expenses BreakdownRevenue By Business VerticalRevenue By Business Vertical (Annual)Revenue By Business Vertical AnnualRevenue By Customer (Annual) %Revenue By Location Of Customer (Product)Revenue By Location Of Customer (Product) %Revenue By Location Of Customer (Product Annual)Revenue By Product CategoryRevenue By Product Category %Revenue By Product Category (Annual)Revenue Mix By Business Vertical Annual %Revenue Mix By Product Category (Annual) %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Gross Profit (2016 - 2025)

Historic Gross Profit for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Q3 2025 value amounting to $2.7 billion.

  • Vertex Pharmaceuticals' Gross Profit rose 1186.48% to $2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 billion, marking a year-over-year increase of 1053.36%. This contributed to the annual value of $9.5 billion for FY2024, which is 1025.44% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Gross Profit stood at $2.7 billion, which was up 1186.48% from $2.6 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' Gross Profit's 5-year high stood at $2.7 billion during Q3 2025, with a 5-year trough of $1.5 billion in Q1 2021.
  • For the 5-year period, Vertex Pharmaceuticals' Gross Profit averaged around $2.1 billion, with its median value being $2.1 billion (2023).
  • In the last 5 years, Vertex Pharmaceuticals' Gross Profit soared by 2925.18% in 2021 and then skyrocketed by 252.13% in 2025.
  • Vertex Pharmaceuticals' Gross Profit (Quarter) stood at $1.8 billion in 2021, then increased by 10.64% to $2.0 billion in 2022, then increased by 6.45% to $2.1 billion in 2023, then rose by 15.76% to $2.5 billion in 2024, then rose by 6.95% to $2.7 billion in 2025.
  • Its Gross Profit stands at $2.7 billion for Q3 2025, versus $2.6 billion for Q2 2025 and $2.4 billion for Q1 2025.